Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2295 SEK | +20.54% | +13.61% | -97.70% |
02:43pm | Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar | MT |
05-02 | Xbrane Biopharma AB Appoints Kristoffer Bissessar Was Elected as New Director | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.70% | 26.8M | |
+17.69% | 47.02B | |
+48.77% | 41.86B | |
+1.11% | 41.76B | |
-4.27% | 28.8B | |
+12.02% | 26.05B | |
-21.47% | 19.15B | |
+4.33% | 12.55B | |
+28.27% | 12.34B | |
-4.32% | 11.82B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Transcript : Xbrane Biopharma AB, Q1 2023 Earnings Call, May 31, 2023